MediciNova’s MN-166 Program Recognized as One of Windhover’s Top 10 … – MarketWatch (press release)

MediciNova's MN-166 Program Recognized as One of Windhover's Top 10
MarketWatch (press release)
Ibudilast is marketed in Japan and South Korea for the treatment of asthma and cerebrovascular disorders for which MediciNova discovered its potential as a

and more »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.